13 April 2026
Johnson & Johnson reports positive 12‑month VARIPULSE results at EHRA 2026
12‑month post‑market study: 84.2% freedom from atrial arrhythmia (90.5% paroxysmal; 75.3% persistent); 0.8% primary adverse events; CE‑mark allows ablation beyond pulmonary veins
